Gout‐associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model

This study aimed to establish a novel gouty ulcer rat model induced by monosodium urate (MSU) deposition and preliminarily explored how MSU crystals affected wound healing. MSU crystals were subcutaneously injected into the back of rats to simulate tophi formation and ulceration. Ultrasound was used to detect the formation of gouty tophi. MSU crystal deposition and histopathological changes were analysed by haematoxylin–eosin staining. After the skin over the tophi became broken in the model group, a full‐thickness tissue defect of the same area was made on the backs of the phosphate buffered saline (PBS) controls. On Days 3, 7, and 14 after wounding, the infiltration of neutrophils and macrophages and the expression of inflammatory markers, including interleukin‐1β (IL‐1β), tumour necrosis factor‐α (TNF‐α), and Nod‐like receptor protein 3 (NLRP3), were examined by immunohistochemical staining and Western blotting, respectively. After the first subcutaneous injection in rats, local tissues showed redness and swelling, indicating inflammation on approximately Day 14. Tophi‐like manifestations appeared on approximately Day 18. Tophi appeared heterogeneously hyperechoic by ultrasound. Swelling and redness in injured tissue areas increased on approximately Day 22, skin tissue necrosis was seen in a small area on approximately Day 26, and skin necrosis was enlarged and the tophi were ulcerated on approximately Day 32, accompanied by yellowish‐white, chalky secretions. Haematoxylin and eosin staining showed dermal deposition of needle‐like crystals with surrounding granulomatous inflammation. On Days 3, 7, and 14 after wounding, immunohistochemical staining showed the infiltration of neutrophils and macrophages, and the expression of inflammation‐related proteins (IL‐1β, TNF‐α, and NLRP3) were upregulated in gouty ulcers compared with those of PBS controls. The gouty ulcers were not completely healed by Day 14 compared with those in the PBS controls. In this study, a novel gouty ulcer rat model was constructed, which also revealed the existence of persistent chronic inflammation.

[1]  R. Holt,et al.  OP0169 AMPUTATION PROCEDURES IN PATIENTS WITH GOUT COMPARED TO PATIENTS WITH DIABETES , 2020 .

[2]  Z. Wen,et al.  Etoricoxib prevents progression of osteolysis in repeated intra-articular monosodium urate-induced gouty arthritis in rats , 2020, Journal of advanced research.

[3]  E. Chiu,et al.  Nonhealing Ulcers in Patients with Tophaceous Gout: A Systematic Review , 2017, Advances in skin & wound care.

[4]  Ju-Young Kim,et al.  Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo , 2016, International journal of biological sciences.

[5]  K. Sukhdeo,et al.  Ulcerated tophaceous gout , 2015, BMJ Case Reports.

[6]  M. Gutierrez,et al.  Animal model of acute gout reproduces the inflammatory and ultrasonographic joint changes of human gout , 2015, Arthritis Research & Therapy.

[7]  O. Stojadinović,et al.  Clinical application of growth factors and cytokines in wound healing , 2014, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[8]  M. Doherty,et al.  Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study , 2014, BDJ.

[9]  S. Juraschek,et al.  Body mass index, obesity, and prevalent gout in the United States in 1988–1994 and 2007–2010 , 2013, Arthritis care & research.

[10]  D. Khanna,et al.  Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey , 2012, Health and Quality of Life Outcomes.

[11]  Nicola Dalbeth,et al.  Mechanisms of joint damage in gout: evidence from cellular and imaging studies , 2012, Nature Reviews Rheumatology.

[12]  Shin-Seok Lee,et al.  Bone destruction by receptor activator of nuclear factor κB ligand-expressing T cells in chronic gouty arthritis , 2011, Arthritis research & therapy.

[13]  Cord Sunderkötter,et al.  An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. , 2011, The Journal of clinical investigation.

[14]  G. B. Sandim,et al.  Ultrasound features of tophi in chronic tophaceous gout , 2011, Skeletal Radiology.

[15]  W. Marston,et al.  Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. , 2009, Journal of vascular surgery.

[16]  E. de Miguel,et al.  Asymptomatic Hyperuricemia: Impact of Ultrasonography , 2008, Nucleosides, nucleotides & nucleic acids.

[17]  G. Lazarus,et al.  Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings. , 2008, Journal of the American Academy of Dermatology.

[18]  N. Kamatani,et al.  Trends in the manifestations of gout in Taiwan. , 2003, Rheumatology.

[19]  H. Schumacher,et al.  Hydroxychloroquine inhibits matrix metalloprotease activity in experimental calcium pyrophosphate dihydrate (CPPD) crystal induced inflammation in the rat subcutaneous air pouch , 2000, InflammoPharmacology.

[20]  E. Middelkoop,et al.  Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. , 1998, The Journal of investigative dermatology.

[21]  R. Tarnuzzer,et al.  Biochemical analysis of acute and chronic wound environments , 1996, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[22]  G. Carrera,et al.  Tophaceous gout: a clinical and radiographic assessment. , 1984, Arthritis and rheumatism.